促性腺激素释放激素激动剂触发可增加接受卵巢刺激以保存生育力的癌症患者可冻存的卵母细胞和胚胎数量
这项回顾性队列研究在学术中心纳入341例接受控制性卵巢刺激的癌症患者,比较促性腺激素释放激素激动剂触发与hCG触发对可冻存卵母细胞和胚胎数的影响。结果显示,在来曲唑联合促性腺激素方案及单用促性腺激素方案中,激动剂触发组的MII卵母细胞数量和百分比均更高;多因素线性回归显示激动剂触发组可冻存MII卵母细胞和2PN胚胎约多3个和2个,与癌症类型和刺激方案无关。
要点
- 在来曲唑联合促性腺激素方案中,激动剂触发组可冻存MII卵母细胞数11.8±5.8 vs hCG组9.9±6.0,百分比89.6% vs 73.0%。
- 在单用促性腺激素方案中,激动剂触发组可冻存MII卵母细胞数13.3±7.9 vs hCG组9.3±6.0,百分比85.7% vs 72.8%。
- 多因素线性回归显示激动剂触发组可冻存MII卵母细胞和2PN胚胎约多3个和2个,与癌症类型和刺激方案无关。
核心结论
- 使用促性腺激素释放激素激动剂触发可增加接受控制性卵巢刺激以保存生育力的癌症患者可冻存的MII卵母细胞和2PN胚胎数量。
研究设计与样本
- 回顾性队列研究,在学术中心纳入341例接受控制性卵巢刺激的癌症患者,其中激动剂触发组99例(29.0%),hCG触发组242例(71%)。
主要发现
- 在来曲唑联合促性腺激素方案组(n=269)中,激动剂触发组可冻存MII卵母细胞数(均值±标准差)11.8±5.8 vs hCG组9.9±6.0,百分比89.6% vs 73.0%。
- 在单用促性腺激素方案组(n=72)中,激动剂触发组可冻存MII卵母细胞数13.3±7.9 vs hCG组9.3±6.0,百分比85.7% vs 72.8%。
- 多因素线性回归显示,激动剂触发组可冻存MII卵母细胞和2PN胚胎约多3个和2个,与癌症类型和刺激方案类型无关。
- 两组基线人口学特征无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the oocyte and embryo yield associated with GnRH-agonist triggers vs. hCG triggers in cancer patients undergoing controlled ovarian stimulation (COS) for fertilization preservation. DESIGN: Retrospective cohort study. SETTING: Academic center. PATIENT(S): Cancer patients undergoing COS with letrozole and gonadotropins or gonadotropin-only protocols for oocyte or embryo cryopreservation. INTERVENTION(S): Gonadotropin-releasing hormone agonist or hCG trigger. MAIN OUTCOME MEASURE(S): Number of metaphase II (MII) oocytes or two-pronuclei (2PN) embryos available for cryopreservation were primary outcomes. Separate multivariate linear regression models were used to assess the effect of trigger type on the primary outcomes, after controlling for confounders of interest. RESULT(S): A total of 341 patients were included, 99 (29.0%) in the GnRH-agonist group and 242 (71%) in the hCG group. There was no difference in the baseline demographics of patients receiving GnRH-agonist or hCG triggers. Within the letrozole and gonadotropins group (n = 269), the number (mean ± SD, 11.8 ± 5.8 vs. 9.9 ± 6.0) and percentage of MII oocytes (89.6% vs. 73.0%) available for cryopreservation was higher with GnRH-agonist triggers compared with hCG triggers. Similar results were noted with GnRH-agonist triggers in the gonadotropin-only group (n = 72) (i.e., a higher number [13.3 ± 7.9 vs. 9.3 ± 6.0] and percentage of MII oocytes [85.7% vs. 72.8%] available for cryopreservation). Multivariate linear regression demonstrated approximately three more MII oocytes and 2PN embryos available for cryopreservation in the GnRH-agonist trigger group, irrespective of cancer and COS protocol type. CONCLUSION(S): Utilization of a GnRH-agonist trigger increases the number of MII oocytes and 2PN embryos available for cryopreservation in cancer patients undergoing COS for fertility preservation.
引用
- Pereira N, Kelly AG, Stone LD, et al. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation. Fertil Steril. 2017. PMID: 28865552. doi:10.1016/j.fertnstert.2017.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。